SOUTH MANGANESE (01091) released its annual performance, with a net profit attributable to shareholders of 167 million Hong Kong dollars, turning from a loss to a profit year-on-year.

18:10 13/03/2026

Nanfang Manganese (01091) released its annual performance for the year ending December 31, 2025. The company achieved revenue of 6.369 billion Hong Kong dollars, a decrease of 51.79% year-on-year. The company's attributable net profit for the year was 167 million Hong Kong dollars, turning from a loss to a profit year-on-year. Earnings per share were 0.0394 Hong Kong dollars.

SOUTH MANGANESE (01091) announced its full-year performance for the year ending December 31, 2025. The company achieved a revenue of HK$6.369 billion, a decrease of 51.79% compared to the previous year. The company's attributable profit for the year was HK$167 million, turning from a loss to a profit year-on-year. Earnings per share were HK$0.0394. The announcement stated that the decrease in revenue was mainly due to a reduction in sales revenue from the trading business.

Huiyu Pharmaceutical (688553.SH): Injection Carfizomib Obtained Drug Registration Certificate.

JINXUN RESOURCE (03636) announces expected comprehensive profit of approximately RMB 300 million to RMB 330 million for the year 2025.

7ROAD (00797) announces a profitable year with an estimated net profit attributable to shareholders of approximately 37 million yuan in the year 2025.

Huiyu Pharmaceutical (688553.SH): Injection Carfizomib Obtained Drug Registration Certificate.

JINXUN RESOURCE (03636) announces expected comprehensive profit of approximately RMB 300 million to RMB 330 million for the year 2025.

7ROAD (00797) announces a profitable year with an estimated net profit attributable to shareholders of approximately 37 million yuan in the year 2025.